Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01378975
Registration number
NCT01378975
Ethics application status
Date submitted
21/06/2011
Date registered
23/06/2011
Date last updated
1/08/2016
Titles & IDs
Public title
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Query!
Scientific title
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Query!
Secondary ID [1]
0
0
MO25743
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malignant Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vemurafenib
Experimental: Cohort 1: Previously Untreated Participants - Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
Experimental: Cohort 2: Previously treated Participants - Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
Treatment: Drugs: Vemurafenib
960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation Criteria in Solid Tumors [RECIST])
Query!
Assessment method [1]
0
0
BORR assessed by IRC is defined as percentage of participants who were responders [with best overall response (BOR) documented as confirmed complete response (CR) or partial response (PR)]. The RECIST v1.1 criteria modified for independent review of body and brain lesions was based on current radiology practices. The modifications to RECIST v1.1 included allowing target lesions in the brain to be >=5 mm by contrast-enhanced magnetic resonance imaging scan (in traditional RECIST v1.1 this is >=10 mm), allowing up to 5 target lesions in the brain (in traditional RECIST v1.1 only 2 target lesions), and examining the lesions within the brain and outside the brain separately for analytical purposes. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm), PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [1]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [1]
0
0
Best Overall Response Rate (BORR) in the Brain of Participants With Previously Treated or Untreated Brain Metastases as Assessed by the IRC Using RECIST v1.1
Query!
Assessment method [1]
0
0
Percentage of participants who were responders with BOR documented as confirmed CR or PR, stable disease (SD), progressive disease (PD). CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Query!
Timepoint [1]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [2]
0
0
Best Overall Response Rate (BORR) in the Brain of Participants With Previously Treated Brain Metastases as Assessed by the IRC Using RECIST v1.1
Query!
Assessment method [2]
0
0
BORR within brain assessed by IRC is defined as percentage of participants who were responders (with BOR documented as confirmed CR or PR). According to RECIST v1.1 criteria modified for brain metastases, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm, PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [2]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [3]
0
0
Best Overall Response Rate Outside the Brain (Assessed by IRC)
Query!
Assessment method [3]
0
0
BORR outside of brain assessed by IRC is defined as percentage of participants who were responders (with BOR documented as confirmed CR or PR). According to RECIST v1.1 criteria modified for brain metastases, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm, PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [3]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR) (Assessed by Investigator and IRC)
Query!
Assessment method [4]
0
0
Duration of response was defined as the time interval between the date of the earliest qualifying response and the earliest date of PD or death from any cause. For participants who were alive without progression following the qualifying response, DOR were censored on the date of last available tumor assessment on or before the data cutoff date.
Query!
Timepoint [4]
0
0
Date of the earliest qualifying response until the earliest date of PD or death from any cause (approximately up to 4 years)
Query!
Secondary outcome [5]
0
0
Progression-Free Survival (PFS) Based on Overall Tumor Response (Assessed by Investigator)
Query!
Assessment method [5]
0
0
Progression-free survival was defined as the time between enrollment on Day 1 and the date of first radiographically documented progressive disease (within or outside the brain), clinical progressive disease, as assessed by the investigator or death whichever occurred first.
Query!
Timepoint [5]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [6]
0
0
Progression-Free Survival (PFS) Based on Tumor Assessment Within Brain Only (Assessed by Investigator )
Query!
Assessment method [6]
0
0
Progression-free survival was defined as the time between enrollment on Day 1 and the date of first radiographically documented progressive disease (within brain), clinical progressive disease, as assessed by the investigator or death whichever occurred first.
Query!
Timepoint [6]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [7]
0
0
Time to Development of New Brain Metastases in Responders
Query!
Assessment method [7]
0
0
Time to development of new lesions within the brain was defined as the interval between the date of first treatment and the earliest date of documentation of new brain lesions. Participants who were known to be free of new lesions were censored on the date of last tumor assessment.
Query!
Timepoint [7]
0
0
Date of first treatment and the earliest date of documentation of new brain lesions (approximately up to 4 years)
Query!
Secondary outcome [8]
0
0
Overall Survival
Query!
Assessment method [8]
0
0
Overall survival was defined as time between enrollment on Day 1 and date of death, irrespective of the cause of death. Participants for whom no death was captured on the clinical database were censored at the latest date they were known to be alive prior to or on the cutoff date.
Query!
Timepoint [8]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [9]
0
0
Best Overall Response Rate (BORR) Within the Brain and Outside Brain (Assessed by Investigator)
Query!
Assessment method [9]
0
0
Percentage of participants who were responders with BOR documented as confirmed CR or PR, stable disease (SD), progressive disease (PD). CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Query!
Timepoint [9]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [10]
0
0
Best Overall Response Rate (BORR) Within the Brain and Outside Brain (Not Necessarily Follows the RECIST Criteria - as Assessed by Investigator)
Query!
Assessment method [10]
0
0
Percentage of participants who were responders (with best overall response (BOR) documented as confirmed complete response [CR] or partial response [PR]) were reported.
Query!
Timepoint [10]
0
0
Baseline up to the disease progression or death from any cause (approximately 4 years)
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Adverse Events (AE)
Query!
Assessment method [11]
0
0
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Query!
Timepoint [11]
0
0
From signing of informed consent form up to 28 days after the last dose of study drug (approximately up to 4 years)
Query!
Eligibility
Key inclusion criteria
- Adult participants, >/= 18 years of age
- Histologically confirmed metastatic melanoma (Stage IV, American Joint Committee on
Cancer) with BRAF V600 mutation (cobas 4800 BRAF V600 Mutation Test)
- Measurable brain metastases, defined as lesions that were accurately measured in at
least one dimension (longest diameter to be recorded) as =0.5 cm in the brain MRI with
contrast, treated or untreated
- Participants may or may not have received prior systemic therapy for metastatic
melanoma and either a) have received no prior treatment for brain metastases or b)
have received prior treatment for brain metastases and have progressed
- Participants may or may not have symptoms related to their brain metastases
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Participants must have recovered from all side effects of their most recent systemic
or local treatment for metastatic melanoma
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Increasing corticosteroid dose during the 7 days prior to first dose of study drug
- Leptomeningeal involvement in participants with no prior treatment for brain
metastases
- Previous malignancy requiring active treatment within the past 2 years, except for
treated and controlled basal or squamous cell carcinoma of the skin, or carcinoma
in-situ of the cervix
- Concurrent administration of any anticancer therapies other than those administered in
the study
- Treatment with any cytotoxic, investigational drug or targeted therapy 4 weeks prior
to first dose of study drug. Radiation therapy =1 week prior to first administration
of vemurafenib; and stereotactic radiotherapy =1 day prior to prior to first
administration of vemurafenib
- Prior treatment with BRAF or MEK inhibitors
- Clinically significant cardiovascular disease or event within the 6 months prior to
first dose of study drug
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
146
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
- Wentworthville
Query!
Recruitment hospital [2]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Wentworthville
Query!
Recruitment postcode(s) [2]
0
0
3002 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Washington
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Ontario
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Bordeaux
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Nice
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Paris
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Essen
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Frankfurt
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Kiel
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Mannheim
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Münster
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Tübingen
Query!
Country [21]
0
0
Israel
Query!
State/province [21]
0
0
Tel-Hashomer
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Lombardia
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Toscana
Query!
Country [24]
0
0
Netherlands
Query!
State/province [24]
0
0
Amsterdam
Query!
Country [25]
0
0
Netherlands
Query!
State/province [25]
0
0
Groningen
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Navarra
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Barcelona
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Madrid
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Northwood
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, single-arm, multicenter study will evaluate the efficacy and safety in
participants with metastatic melanoma who developed brain metastases. Participants may or may
not have received prior systemic treatment for metastatic melanoma [except treatment with
v-raf murine sarcoma viral oncogene homolog B (BRAF) or mitogen-activated protein kinase
(MEK) inhibitors]. Participants will receive oral doses of 960 mg vemurafenib twice daily
until disease progression, unacceptable toxicity or consent withdrawal.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01378975
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01378975
Download to PDF